文献速递乳腺癌支持与姑息治疗

哌柏西利联合来曲唑对患者报告健康相关生活质量的影响:PALOMA-2 研究结果

Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial.
PubMed 文献 · Ann Oncol · 2018-01-01

患者报告结局显示两臂 FACT-Breast 总分、FACT-General 总分及 EQ-5D 评分较基线的变化无显著差异,但哌柏西利联合来曲唑组疼痛评分改善更显著。无进展患者及客观缓解患者的生活质量恶化时间显著延迟。

要点

  • 哌柏西利联合来曲唑维持健康相关生活质量,且疼痛评分改善优于单用来曲唑。
  • 两臂 FACT-Breast 总分、FACT-General 总分及 EQ-5D 评分变化无显著差异。
  • 无进展或客观缓解患者的生活质量恶化显著延迟。

核心结论

  • 在未经治疗的绝经后 ER+/HER2- 转移性乳腺癌患者中,哌柏西利联合来曲唑维持健康相关生活质量并改善疼痛评分。

研究设计与样本

  • PALOMA-2 研究为随机 2:1 对照试验,哌柏西利联合来曲唑组 444 例,安慰剂联合来曲唑组 222 例。
  • 患者报告结局采用 FACT-Breast 和 EQ-5D 问卷,在基线、第 2 和第 3 周期第 1 天及第 5 周期起每隔一周期第 1 天评估。

主要发现

  • 截至 2016 年 2 月 26 日,中位随访 23 个月,两臂基线评分相当。
  • 两臂 FACT-Breast 总分、FACT-General 总分及 EQ-5D 评分较基线变化无显著差异。
  • 哌柏西利联合来曲唑组疼痛评分改善显著优于对照组(-0.256 对 -0.098;P = 0.0183)。
  • 无进展患者较进展患者、部分或完全缓解患者较无缓解患者,FACT-Breast 总分恶化显著延迟。
  • 伴或不伴中性粒细胞减少患者的 FACT-Breast 和 EQ-5D 指数评分无显著差异。

临床怎么用

  • 对于未经治疗的绝经后 ER+/HER2- 转移性乳腺癌患者,哌柏西利联合来曲唑在维持生活质量的同时可改善疼痛。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patient-reported outcomes are integral in benefit-risk assessments of new treatment regimens. The PALOMA-2 study provides the largest body of evidence for patient-reported health-related quality of life (QOL) for patients with metastatic breast cancer (MBC) receiving first-line endocrine-based therapy (palbociclib plus letrozole and letrozole alone). PATIENTS AND METHODS: Treatment-naïve postmenopausal women with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) MBC were randomized 2 : 1 to palbociclib plus letrozole (n = 444) or placebo plus letrozole (n = 222). Patient-reported outcomes were assessed at baseline, day 1 of cycles 2 and 3, and day 1 of every other cycle from cycle 5 using the Functional Assessment of Cancer Therapy (FACT)-Breast and EuroQOL 5 dimensions (EQ-5D) questionnaires. RESULTS: As of 26 February 2016, the median duration of follow-up was 23 months. Baseline scores were comparable between the two treatment arms. No significant between-arm differences were observed in change from baseline in FACT-Breast Total, FACT-General Total, or EQ-5D scores. Significantly greater improvement in pain scores was observed in the palbociclib plus letrozole arm (-0.256 versus -0.098; P = 0.0183). In both arms, deterioration of FACT-Breast Total score was significantly delayed in patients without progression versus those with progression and patients with partial or complete response versus those without. No significant difference was observed in FACT-Breast and EQ-5D index scores in patients with and without neutropenia. CONCLUSIONS: Overall, women with MBC receiving first-line endocrine therapy have a good QOL. The addition of palbociclib to letrozole maintains health-related QOL and improves pain scores in treatment-naïve postmenopausal patients with ER+/HER2- MBC compared with letrozole alone. Significantly greater delay in deterioration of health-related QOL was observed in patients without progression versus those who progressed and in patients with an objective response versus non-responders. ClinicalTrials.gov: NCT01740427 (https://clinicaltrials.gov/ct2/show/NCT01740427).

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Rugo HS, Diéras V, Gelmon KA, et al. Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial. Ann Oncol. 2018. PMID: 29360932. doi:10.1093/annonc/mdy012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。